Molecular farming in plants: The long road to the market

Biotechnology in Agriculture and Forestry

Volumn 68, Issue , 2014, Pages 27-41

  Fischer, Rainer ^a,b   Buyel, Johannes F ^b   Schillberg, Stefan ^a   Twyman, Richard M ^c  

^a FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c TRM Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85003419303     PISSN: 0934943X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-662-43836-7_3     Document Type: Chapter

References (71)

1. Aviezer D, Almon-Brill E, Shaaltiel Y et al (2009a) Novel enzyme replacement therapy for Gaucher disease: ongoing Phase III clinical trial with recombinant human glucocerebrosidase expressed in plant cells. Mol Genet Metab 96:S13-S14
2. Aviezer D, Brill-Almon E, Shaaltiel Y et al (2009b) A plant-derived recombinant human glucocerebrosidase enzyme—a preclinical and phase I investigation. PLoS One 4:e4792
3. Azzoni AR, Kusnadi AR, Miranda EA et al (2002) Recombinant aprotinin produced in transgenic corn seed: extraction and purification studies. Biotechnol Bioeng 80:268-276
4. Azzoni AR, Farinas CS, Miranda EA (2005) Transgenic corn seed for recombinant protein production: relevant aspects on the aqueous extraction of native components. J Sci Food Agric 85:609-614
5. Bevan MW, Flavell RB, Chilton MD (1983) A chimaeric antibiotic resistance gene as a selectable marker for plant cell transformation. Nature 304:184-187
6. Buyel JF, Fischer R (2012) Predictive models for transient protein expression in tobacco (Nico-tiana tabacum L.) can optimize process time, yield, and downstream costs. Biotechnol Bioeng 109:2575-2588
7. Buyel JF, Fischer R (2014a) Flocculation increases the efficacy of depth filtration during the downstream processing of recombinant pharmaceutical proteins produced in tobacco. Plant Biotechnol J 12:240-252
8. Buyel JF, Fischer R (2014b) Scale-down models to optimize a filter train for the downstream purification of recombinant pharmaceutical proteins produced in tobacco leaves. Biotechnol J 9:415-425
9. Buyel JF, Kaever T, Buyel JJ et al (2013a) Predictive models for the accumulation of a fluorescent marker protein in tobacco leaves according to the promoter/5’UTR combination. Biotechnol Bioeng 110:471-482
10. Buyel JF, Woo JA, Cramer SM et al (2013b) The use of quantitative structure-activity relationship models to develop optimized processes for the removal of tobacco host cell proteins during biopharmaceutical production. J Chromatogr A 1322:18-28
11. Buyel JF, Gruchow HM, Boes A et al (2014) Rational design of a host cell protein heat precipitation step can simplify the subsequent purification of recombinant proteins from tobacco. Biotechnol Bioeng 88:162-170
12. Cardi T, Lenzi P, Maliga P (2010) Chloroplasts as expression platforms for plant-produced vaccines. Expert Rev Vaccines 9:893-911
13. Castilho A, Strasser R, Stadlmann J et al (2010) In planta protein sialylation through overexpression of the respective mammalian pathway. J Biol Chem 285:15923-15930
14. Cox KM, Sterling JD, Regan JT et al (2006) Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 24:1591-1597
15. D’Aoust MA, Couture MM, Charland N et al (2010) The production of hemagglutinin-based viruslike particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J 8:607-619
16. D’Aoust MA, Lavoie PO, Couture MM et al (2008) Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J 6:930-940
17. EMEA (2002) Committee for Proprietary Medicinal Products (CPMP). Points to consider on quality aspects of medicinal products containing active substances produced by stable transgene expression in higher plants (EMEA/CPMP/BWP/764/02).EMA, London, UK
18. EMEA (2009) Committee for Proprietary Medicinal Products (CPMP). Guideline on the quality of biological active substances produced by stable transgene expression in higher plants (EMEA/ CHMP/BWP/48316/2006).EMA, London, UK
19. FDA/USDA (2002) Draft guidance. Drugs, biologics, and medical devices derived from bioengineered plants for use in humans and animals. FDA, Rockville, MD. http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM055424.pdf
20. Fischer R, Schillberg S, Hellwig S et al (2012) GMP issues for plant-derived recombinant proteins. Biotechnol Adv 30:434-439
21. Giritch A, Marillonnet S, Engler C et al (2006) Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc Natl Acad Sci USA 103:14701-14706
22. Gomord V, Fitchette AC, Menu-Bouaouiche L et al (2010) Plant-specific glycosylation patterns in the context of therapeutic protein production. Plant Biotechnol J 8:564-587
23. Hiatt AH, Caffertey R, Bowdish K (1989) Production of antibodies in transgenic plants. Nature 342:76-78
24. Hofbauer A, Stoger E (2013) Subcellular accumulation and modification of pharmaceutical proteins in different plant tissues. Curr Pharm Des 19:5495-5502
25. Hood EE (2002) From green plants to industrial enzymes. Enzyme Microb Technol 30:279-283
26. Hood EE, Witcher DR, Maddock S et al (1997) Commercial production of avidin from transgenic maize: characterization of transformant, production, processing, extraction and purification. Mol Breed 3:291-306
27. Hood EE, Woodard SL, Horn ME (2002) Monoclonal antibody manufacturing in transgenic plants—myths and realities. Curr Opin Biotechnol 13:630-635
28. Huang Z, Phoolcharoen W, Lai H et al (2010) High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system. Biotechnol Bioeng 106:9-17
29. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (2012) Q11. Development and manufacture of drug substances (chemical entities and biotechnological/biological entities). Fed Regist 77:69634-69635
30. Kusnadi AR, Evangelista RL, Hood EE et al (1998) Processing of transgenic corn seed and its effect on the recovery of recombinant ß-glucuronidase. Biotechnol Bioeng 60:44-52
31. Lamphear BJ, Streatfield SJ, Jilka JM et al (2002) Delivery of subunit vaccines in maize seed. J Control Release 85:169-180
32. Landry N, Ward BJ, Trepanier S et al (2010) Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 5:e15559
33. Ma JKC, Drake PMW, Christou P (2003) The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet 4:794-805
34. Menkhaus TJ, Bai Y, Zhang CM et al (2004) Considerations for the recovery of recombinant proteins from plants. Biotechnol Prog 20:1001-1014
35. Nikolov ZL, Woodard SL (2004) Downstream processing of recombinant proteins from transgenic feedstock. Curr Opin Biotechnol 15:479-486
36. Ogawa M, Kumamaru T, Satoh H et al (1987) Purification of protein body-I of rice seed and its polypeptide composition. Plant Cell Physiol 28:1517-1527
37. Pandey A, Singh N, Mittal SK (2010) Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum Vaccin 6:178-188
38. Paul MJ, Teh AY, Twyman RM et al (2013) Target product selection—where can molecular pharming make the difference? Curr Pharm Des 19:5478-5485
39. Pogue GP, Vojdani F, Palmer KE et al (2010) Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems. Plant Biotechnol J 8:638-654
40. Rademacher T, Sack M, Arcalis E et al (2008) Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-gly-cans. Plant Biotechnol J 6:189-201
41. Ramessar K, Rademacher T, Sack M et al (2008) Cost-effective production of a vaginal protein microbicide to prevent HIV transmission. Proc Natl Acad Sci USA 105:3727-3732
42. Ramessar K, Sabalza M, Miralpeix B et al (2010) Can microbicides turn the tide against HIV? Curr Pharm Des 16:468-485
43. Rappuoli R, Dormitzer PR (2012) Influenza: options to improve pandemic preparation. Science 336:1531-1533
44. Sainsbury F, Lomonossoff GP (2008) Extremely high-level and rapid protein production in plants without the use of viral replication. Plant Physiol 148:1212-1218
45. Schillberg S, Raven N, Fischer R et al (2013) Molecular farming of pharmaceutical proteins using plant suspension cell and tissue cultures. Curr Pharm Des 19:5531-5542
46. Shaaltiel Y, Bartfeld D, Hashmueli S et al (2007) Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell system. Plant Biotechnol J 5:579-590
47. Shoji Y, Chichester JA, Bi H et al (2008) Plant-expressed HA as a seasonal influenza vaccine candidate. Vaccine 26:2930-2934
48. Shoji Y, Chichester JA, Jones M et al (2011) Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Hum Vaccin 7:41-50
49. Soria-Guerra RE, Rosales-Mendoza S, Moreno-Fierros L et al (2011) Oral immunogenicity of tomato-derived sDPT polypeptide containing Corynebacterium diphtheriae, Bordetella pertussis and Clostridium tetani exotoxin epitopes. Plant Cell Rep 30:417-424
50. Spok A, Twyman RM, Fischer R et al (2008) Evolution of a regulatory framework for plant-made pharmaceuticals. Trends Biotechnol 26:506-517
51. Sriraman R, Bardor M, Sack M et al (2004) Recombinant anti-hCG antibodies retained in the endoplasmic reticulum of transformed plants lack core-xylose and core-a(1,3)-fucose residues. Plant Biotechnol J 2:279-287
52. Stoger E, Sack M, Nicholson L et al (2005) Recent progress in plantibody technology. Curr Pharm Des 11:2439-2457
53. Strasser R, Castilho A, Stadlmann J et al (2009) Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous ß1,4-galactosylated N-glycan profile. J Biol Chem 284:20479-20485
54. Streatfield SJ, Lane JR, Brooks CA et al (2003) Corn as a production system for human and animal vaccines. Vaccine 21:812-815
55. Tiwari S, Verma PC, Singh PK et al (2009) Plants as bioreactors for the production of vaccine antigens. Biotechnol Adv 27:449-467
56. Tremblay R, Wang D, Jevnikar AM et al (2010) Tobacco, a highly efficient green bioreactor for production of therapeutic proteins. Biotechnol Adv 28:214-221
57. Triguero A, Cabrera G, Cremata JA et al (2005) Plant-derived mouse IgG monoclonal antibody fused to KDEL endoplasmic reticulum-retention signal is N-glycosylated homogeneously throughout the plant with mostly high-mannose-type N-glycans. Plant Biotechnol J 3:449-457
58. Twyman RM, Stoger E, Schillberg S et al (2003) Molecular farming in plants: host systems and expression technology. Trends Biotechnol 21:570-578
59. Twyman RM, Schillberg S, Fischer R (2005) Transgenic plants in the biopharmaceutical market. Expert Opin Emerg Drugs 10:185-218
60. Twyman RM, Schillberg S, Fischer R (2013) Optimizing the yield of recombinant pharmaceutical proteins in plants. Curr Pharm Des 19:5486-5494
61. Verma D, Moghimi B, LoDuca PA et al (2010) Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proc Natl Acad Sci USA 107:7101-7106
62. Vezina LP, Faye L, Lerouge P et al (2009) Transient co-expression for fast and high-yield production of antibodies with human-like N-glycans in plants. Plant Biotechnol J 7:442-455
63. Whaley KJ, Hiatt A, Zeitlin L (2011) Emerging antibody products and Nicotiana manufacturing. Hum Vaccin 7:349-356
64. Wilken LR, Nikolov ZL (2006) Factors influencing recombinant human lysozyme extraction and cation exchange adsorption. Biotechnol Prog 22:745-752
65. Wilken LR, Nikolov ZL (2010) Evaluation of alternatives for human lysozyme purification from transgenic rice: impact of phytic acid and buffer. Biotechnol Prog 26:1303-1311
66. Wilken LR, Nikolov ZL (2012) Recovery and purification of plant-made recombinant proteins. Biotechnol Adv 30:419-433
67. Witcher D, Hood EE, Peterson D et al (1998) Commercial production of ß-glucuronidase (GUS): a model system for the production of proteins in plants. Mol Breed 4:301-312
68. Xu J, Ge X, Dolan MC (2011) Towards high-yield production of pharmaceutical proteins with plant cell suspension cultures. Biotechnol Adv 29:278-299
69. Yusibov V, Streatfield SJ, Kushnir N (2011) Clinical development of plant-produced recombinant pharmaceuticals. Vaccines, antibodies and beyond. Hum Vaccin 7:313-321
70. Zhong Q, Xu L, Zhang C et al (2007) Purification of recombinant aprotinin from transgenic corn germ fraction using ion exchange and hydrophobic interaction chromatography. Appl Microbiol Biotechnol 76:607-613
71. Zimmermann J, Saalbach I, Jahn D et al (2009) Antibody expressing pea seeds as fodder for prevention of gastrointestinal parasitic infections in chickens. BMC Biotechnol 9:79